# CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

> **NCT00558896** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 378 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** dexamethasone
- **DRUG:** pomalidomide

## Key facts

- **NCT ID:** NCT00558896
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-09
- **Final completion:** 2017-10-25
- **Target enrollment:** 378 (ACTUAL)
- **Last updated:** 2018-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558896, "CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00558896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*